Cargando…
Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study
BACKGROUND: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear. METHODS: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent C...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649757/ https://www.ncbi.nlm.nih.gov/pubmed/31360853 http://dx.doi.org/10.1093/jncics/pky023 |
_version_ | 1783438045920362496 |
---|---|
author | Schrijver, Lieske H Olsson, Håkan Phillips, Kelly-Anne Terry, Mary Beth Goldgar, David E Kast, Karin Engel, Christoph Mooij, Thea M Adlard, Julian Barrowdale, Daniel Davidson, Rosemarie Eeles, Ros Ellis, Steve Evans, D Gareth Frost, Debra Izatt, Louise Porteous, Mary E Side, Lucy E Walker, Lisa Berthet, Pascaline Bonadona, Valérie Leroux, Dominique Mouret-Fourme, Emmanuelle Venat-Bouvet, Laurence Buys, Saundra S Southey, Melissa C John, Esther M Chung, Wendy K Daly, Mary B Bane, Anita van Asperen, Christi J Gómez Garcia, Encarna B Mourits, Marian J E van Os, Theo A M Roos-Blom, Marie-José Friedlander, Michael L McLachlan, Sue-Anne Singer, Christian F Tan, Yen Y Foretova, Lenka Navratilova, Marie Gerdes, Anne-Marie Caldes, Trinidad Simard, Jacques Olah, Edith Jakubowska, Anna Arver, Brita Osorio, Ana Noguès, Catherine Andrieu, Nadine Easton, Douglas F van Leeuwen, Flora E Hopper, John L Milne, Roger L Antoniou, Antonis C Rookus, Matti A |
author_facet | Schrijver, Lieske H Olsson, Håkan Phillips, Kelly-Anne Terry, Mary Beth Goldgar, David E Kast, Karin Engel, Christoph Mooij, Thea M Adlard, Julian Barrowdale, Daniel Davidson, Rosemarie Eeles, Ros Ellis, Steve Evans, D Gareth Frost, Debra Izatt, Louise Porteous, Mary E Side, Lucy E Walker, Lisa Berthet, Pascaline Bonadona, Valérie Leroux, Dominique Mouret-Fourme, Emmanuelle Venat-Bouvet, Laurence Buys, Saundra S Southey, Melissa C John, Esther M Chung, Wendy K Daly, Mary B Bane, Anita van Asperen, Christi J Gómez Garcia, Encarna B Mourits, Marian J E van Os, Theo A M Roos-Blom, Marie-José Friedlander, Michael L McLachlan, Sue-Anne Singer, Christian F Tan, Yen Y Foretova, Lenka Navratilova, Marie Gerdes, Anne-Marie Caldes, Trinidad Simard, Jacques Olah, Edith Jakubowska, Anna Arver, Brita Osorio, Ana Noguès, Catherine Andrieu, Nadine Easton, Douglas F van Leeuwen, Flora E Hopper, John L Milne, Roger L Antoniou, Antonis C Rookus, Matti A |
author_sort | Schrijver, Lieske H |
collection | PubMed |
description | BACKGROUND: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear. METHODS: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed. RESULTS: For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26% (95% CI = 6% to 51%) and 39% (95% CI = 23% to 58%), respectively. For BRCA2 mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95% CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated: HR = 1.06, 95% CI = 0.85 to 1.33; full cohort: HR = 1.52, 95% CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-term pregnancy (BRCA1: both retrospective analyses, P < .001 and P = .001, respectively; BRCA2: full retrospective analysis, P = .002). CONCLUSIONS: Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40–50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and nonhormonal contraceptive methods should be discussed. |
format | Online Article Text |
id | pubmed-6649757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-66497572019-07-29 Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study Schrijver, Lieske H Olsson, Håkan Phillips, Kelly-Anne Terry, Mary Beth Goldgar, David E Kast, Karin Engel, Christoph Mooij, Thea M Adlard, Julian Barrowdale, Daniel Davidson, Rosemarie Eeles, Ros Ellis, Steve Evans, D Gareth Frost, Debra Izatt, Louise Porteous, Mary E Side, Lucy E Walker, Lisa Berthet, Pascaline Bonadona, Valérie Leroux, Dominique Mouret-Fourme, Emmanuelle Venat-Bouvet, Laurence Buys, Saundra S Southey, Melissa C John, Esther M Chung, Wendy K Daly, Mary B Bane, Anita van Asperen, Christi J Gómez Garcia, Encarna B Mourits, Marian J E van Os, Theo A M Roos-Blom, Marie-José Friedlander, Michael L McLachlan, Sue-Anne Singer, Christian F Tan, Yen Y Foretova, Lenka Navratilova, Marie Gerdes, Anne-Marie Caldes, Trinidad Simard, Jacques Olah, Edith Jakubowska, Anna Arver, Brita Osorio, Ana Noguès, Catherine Andrieu, Nadine Easton, Douglas F van Leeuwen, Flora E Hopper, John L Milne, Roger L Antoniou, Antonis C Rookus, Matti A JNCI Cancer Spectr Article BACKGROUND: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear. METHODS: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed. RESULTS: For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26% (95% CI = 6% to 51%) and 39% (95% CI = 23% to 58%), respectively. For BRCA2 mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95% CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated: HR = 1.06, 95% CI = 0.85 to 1.33; full cohort: HR = 1.52, 95% CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-term pregnancy (BRCA1: both retrospective analyses, P < .001 and P = .001, respectively; BRCA2: full retrospective analysis, P = .002). CONCLUSIONS: Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40–50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and nonhormonal contraceptive methods should be discussed. Oxford University Press 2018-06-28 /pmc/articles/PMC6649757/ /pubmed/31360853 http://dx.doi.org/10.1093/jncics/pky023 Text en copy; The Author(s) 2018. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Article Schrijver, Lieske H Olsson, Håkan Phillips, Kelly-Anne Terry, Mary Beth Goldgar, David E Kast, Karin Engel, Christoph Mooij, Thea M Adlard, Julian Barrowdale, Daniel Davidson, Rosemarie Eeles, Ros Ellis, Steve Evans, D Gareth Frost, Debra Izatt, Louise Porteous, Mary E Side, Lucy E Walker, Lisa Berthet, Pascaline Bonadona, Valérie Leroux, Dominique Mouret-Fourme, Emmanuelle Venat-Bouvet, Laurence Buys, Saundra S Southey, Melissa C John, Esther M Chung, Wendy K Daly, Mary B Bane, Anita van Asperen, Christi J Gómez Garcia, Encarna B Mourits, Marian J E van Os, Theo A M Roos-Blom, Marie-José Friedlander, Michael L McLachlan, Sue-Anne Singer, Christian F Tan, Yen Y Foretova, Lenka Navratilova, Marie Gerdes, Anne-Marie Caldes, Trinidad Simard, Jacques Olah, Edith Jakubowska, Anna Arver, Brita Osorio, Ana Noguès, Catherine Andrieu, Nadine Easton, Douglas F van Leeuwen, Flora E Hopper, John L Milne, Roger L Antoniou, Antonis C Rookus, Matti A Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study |
title | Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study |
title_full | Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study |
title_fullStr | Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study |
title_full_unstemmed | Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study |
title_short | Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study |
title_sort | oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a brca1 and brca2 mutation carrier cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649757/ https://www.ncbi.nlm.nih.gov/pubmed/31360853 http://dx.doi.org/10.1093/jncics/pky023 |
work_keys_str_mv | AT schrijverlieskeh oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT olssonhakan oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT phillipskellyanne oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT terrymarybeth oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT goldgardavide oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT kastkarin oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT engelchristoph oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT mooijtheam oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT adlardjulian oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT barrowdaledaniel oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT davidsonrosemarie oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT eelesros oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT ellissteve oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT evansdgareth oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT frostdebra oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT izattlouise oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT porteousmarye oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT sidelucye oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT walkerlisa oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT berthetpascaline oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT bonadonavalerie oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT lerouxdominique oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT mouretfourmeemmanuelle oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT venatbouvetlaurence oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT buyssaundras oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT southeymelissac oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT johnestherm oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT chungwendyk oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT dalymaryb oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT baneanita oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT vanasperenchristij oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT gomezgarciaencarnab oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT mouritsmarianje oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT vanostheoam oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT roosblommariejose oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT friedlandermichaell oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT mclachlansueanne oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT singerchristianf oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT tanyeny oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT foretovalenka oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT navratilovamarie oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT gerdesannemarie oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT caldestrinidad oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT simardjacques oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT olahedith oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT jakubowskaanna oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT arverbrita oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT osorioana oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT noguescatherine oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT andrieunadine oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT eastondouglasf oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT vanleeuwenflorae oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT hopperjohnl oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT milnerogerl oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT antoniouantonisc oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT rookusmattia oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy AT oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy |